105 related articles for article (PubMed ID: 8284832)
41. Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study.
Grant JE; Odlaug BL; Potenza MN; Hollander E; Kim SW
Br J Psychiatry; 2010 Oct; 197(4):330-1. PubMed ID: 20884959
[TBL] [Abstract][Full Text] [Related]
42. Nalmefene for alcohol dependence.
Harv Ment Health Lett; 2000 Mar; 16(9):7. PubMed ID: 10677202
[No Abstract] [Full Text] [Related]
43. Cost-Effectiveness of Nalmefene: Exaggerated Expectations or Fallacy?
Naudet F; Granger B; Braillon A
Alcohol Alcohol; 2016 Sep; 51(5):623-4. PubMed ID: 27261473
[No Abstract] [Full Text] [Related]
44. A comparison between phase-III trials and a phase-IV study of nalmefene in alcohol use disorder patients. Is there a difference?
Barrio Giménez P; Ortega L; Guardia J; Roncero C; Yuguero L; Gual A
Adicciones; 2019 Sep; 31(4):284-288. PubMed ID: 30059574
[TBL] [Abstract][Full Text] [Related]
45. ▼Nalmefene-time for last orders?
Drug Ther Bull; 2016 Sep; 54(9):97. PubMed ID: 27609425
[No Abstract] [Full Text] [Related]
46. Nalmefene. JF 1, nalmetrene, NIH 10365, ORF 11676, Arthrene, Cervene, Incystene, Revex.
Drugs R D; 1999 Jan; 1(1):32-3. PubMed ID: 10565979
[No Abstract] [Full Text] [Related]
47. Use of Nalmefene in Routine Practice: Results from a French Prospective Cohort Study and a National Database Analysis.
Aubin HJ; Dureau-Pournin C; Falissard B; Paille F; Rigaud A; Micon S; Pénichon M; Andersohn F; Truchi C; Blin P
Alcohol Alcohol; 2021 Aug; 56(5):545-555. PubMed ID: 33969378
[TBL] [Abstract][Full Text] [Related]
48. Nalmefene: radioimmunoassay for a new opioid antagonist.
Dixon R; Hsiao J; Taaffe W; Hahn E; Tuttle R
J Pharm Sci; 1984 Nov; 73(11):1645-6. PubMed ID: 6520774
[TBL] [Abstract][Full Text] [Related]
49. A dose run-up and safety evaluation of nalmefene HCl in human volunteers.
Fudala PJ; Johnson RE; Heishman SJ; Cone EJ; Henningfield JE
NIDA Res Monogr; 1989; 95():451-2. PubMed ID: 2641028
[No Abstract] [Full Text] [Related]
50. Comparison of single and combination drug treatment strategies in experimental brain trauma.
Faden AI
J Neurotrauma; 1993; 10(2):91-100. PubMed ID: 8411221
[TBL] [Abstract][Full Text] [Related]
51. Neuroprotection of nalmefene for postoperative patients with spontaneous intracerebral hemorrhage.
Zheng J; Li H; Guo R; Chen R; Lin S; Liu M; You C
Int J Neurosci; 2015; 125(12):918-23. PubMed ID: 25375267
[TBL] [Abstract][Full Text] [Related]
52. Safety and Persistence of Nalmefene Treatment for Alcohol Dependence. Results from Two Post-authorisation Safety Studies.
Chick J; Andersohn F; Guillo S; Borchert K; Toussi M; Braun S; Haas JS; Kuppan K; Lemming OM; Reines EH; Tubach F
Alcohol Alcohol; 2021 Aug; 56(5):556-564. PubMed ID: 34196359
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis.
Monroe EW
J Am Acad Dermatol; 1989 Jul; 21(1):135-6. PubMed ID: 2745760
[No Abstract] [Full Text] [Related]
54. Can Intranasal Nalmefene Reduce the Number of Opioid Overdose Deaths?
Sellers EM; Romach MK
Clin Pharmacol Drug Dev; 2024 Mar; 13(3):315-316. PubMed ID: 38289185
[No Abstract] [Full Text] [Related]
55. [Opiate antagonists].
Sonka K
Cas Lek Cesk; 1984 Oct; 123(42):1265-9. PubMed ID: 6439410
[No Abstract] [Full Text] [Related]
56. The effect of age on the pharmacokinetics of the opioid antagonist nalmefene.
Frye RF; Matzke GR; Jallad NS; Wilhelm JA; Bikhazi GB
Br J Clin Pharmacol; 1996 Sep; 42(3):301-6. PubMed ID: 8877019
[TBL] [Abstract][Full Text] [Related]
57. Nalmefene non-enantioselectively targets myeloid differentiation protein 2 and inhibits toll-like receptor 4 signaling: wet-lab techniques and
Zhang X; Wang H; Wang Y; Li H; Wu S; Gao J; Zhang T; Xie J; Wang X
Phys Chem Chem Phys; 2021 Jun; 23(21):12260-12269. PubMed ID: 34013938
[TBL] [Abstract][Full Text] [Related]
58. Treatment of Compulsive Pornography Use With Naltrexone: A Case Report.
Kraus SW; Meshberg-Cohen S; Martino S; Quinones LJ; Potenza MN
Am J Psychiatry; 2015 Dec; 172(12):1260-1. PubMed ID: 26619775
[No Abstract] [Full Text] [Related]
59. FDA Approves Nalmefene, a Longer-Lasting Opioid Reversal Nasal Spray.
Harris E
JAMA; 2023 Jun; 329(23):2012. PubMed ID: 37256577
[No Abstract] [Full Text] [Related]
60. Variable Response to Naltrexone in Patients With Hailey-Hailey Disease.
Cao S; Lilly E; Chen ST
JAMA Dermatol; 2018 Mar; 154(3):362-363. PubMed ID: 29344611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
